Menu

Blog

Page 2694

Mar 4, 2023

Bowel cancer breakthrough as scientists find chemotherapy response could be predicted by existing NHS test

Posted by in categories: biotech/medical, innovation

Researchers hope KRAS test can serve renewed function as soon as possible Scientists have found an existing gene test frequently used on the NHS can also shed light on whether a bowel cancer patient will respond positively or negatively to chemotherapy. Researchers from The Institute of Cancer Research, Imperial College London and the Netherlands Cancer Institute have found the KRAS test can have use beyond its current function of predicting how patients will react to cancer drug cetuximab.

Mar 4, 2023

Giant flying insect found on Walmart building turns out to be Jurassic-era find

Posted by in category: habitats

An insect has been identified as the species Polystoechotes punctata, which belongs to a family of insects that predates the dinosaurs.

Mar 4, 2023

Can The Present Affect the Past

Posted by in category: health

An exploration of the ideas of physicist John Wheeler and how it may be that events happening in the present, fix events that happened in the past and that the whole of time in the universe is an exercise in it creating itself.

My Patreon Page:

Continue reading “Can The Present Affect the Past” »

Mar 4, 2023

How the longevity industry can deliver lives that are healthier — physically and mentally

Posted by in categories: life extension, neuroscience

While the mental has often played second fiddle to the physical when it comes to longevity research, this is changing – and not a moment too soon.

The physical and mental aspects of aging are interconnected, and given the strong connection between psychology and the physical pace of aging, poor mental health is starting to be recognised as a major driver of aging.

A raft of developments have demonstrated that physical lifespan and healthspan can be extended and improved, and now it is time for the longevity industry to achieve similar success when it comes to mental health. Sergey Jakimov, the CEO of Swiss investment group LongeVC agrees, and tells us why it’s time for VCs to get excited about backing startups delivering cutting-edge solutions for mental healthcare.

Mar 4, 2023

New Assessment for Immunotherapy Response Identified

Posted by in category: biotech/medical

As a survival mechanism, some tumors, particularly many solid tumors, have evolved to express the ligands capable of turning off the immune response. While immune regulation benefits us under normal conditions, any hindrance of the immune response in the presence of cancer can become detrimental. Understanding these biological processes has led to the development of a promising immunotherapeutic modality: the immune checkpoint inhibitor (ICI). ICIs work by blocking the signals that dampen the immune response.

One prominent checkpoint pathway consists of programmed death 1 (PD1), located on immune cells, and programmed death ligand 1 (PD-L1), expressed on tumor cells. The FDA has approved numerous ICIs to block the interaction of PD-1 and PD-L1 for patients with various solid tumors, including skin, lung, and liver cancers.

Predicting the patients most likely to benefit from PD-1/PD-L1 interventions remains a high priority. Depending on the type of cancer, different tests can predict a patient’s likelihood of responding to ICIs. In some cancers, a readout used to access ICI responsiveness is a patient’s tumor mutational burden (TMB), an estimate of how many mutations appear in the cancer genome. However, better predictive models could help identify more patients who could benefit from these therapies.

Mar 4, 2023

Tapping into the molecular fountain of youth

Posted by in categories: biotech/medical, life extension

At just 40 years old, Kristen Fortney has spent more than half of her life thinking about the science of aging. But why?

“When I get asked this question I usually blame it on reading too much science fiction,” the CEO and co-founder of the clinical-stage biotech BioAge Labs said with a laugh. “My co-founder, Eric Morgen, and I have been talking about aging since high school.”

Mar 4, 2023

The importance of vaccinations for influenza

Posted by in category: biotech/medical

Every year, a huge number of people get sick and die from influenza (flu). The good news is, protecting yourself from flu is easy and safe. Just get your flu vaccine!

More information: https://www.who.int/health-topics/influenza-seasonal#tab=tab_1

Mar 4, 2023

The 10 most innovative companies in artificial intelligence of 2023

Posted by in categories: innovation, robotics/AI

A ranking of the most innovative companies in AI, including OpenAI, DeepMind, Nvidia, Builder.ai, Voxel, and others.

Mar 4, 2023

George Church: Biomanufacturing, CRISPR,1 million cell edits, Woolly mammoth-Learning with Lowell-164

Posted by in categories: engineering, genetics, life extension

George Church is a geneticist known for his pioneering work in developing new technologies for genome sequencing, editing, and synthesis. He has also been involved in research on genome engineering and gene therapy.

Links.
https://wyss.harvard.edu/team/core-faculty/george-church/
https://arep.med.harvard.edu/

Continue reading “George Church: Biomanufacturing, CRISPR,1 million cell edits, Woolly mammoth-Learning with Lowell-164” »

Mar 4, 2023

First measurements of hydrogen-boron fusion in a magnetically confined fusion plasma

Posted by in categories: nuclear energy, particle physics, sustainability

As fusion developers around the world race to commercialize fusion energy, TAE Technologies has pioneered the pursuit of the cleanest and most economical path to providing electricity with hydrogen-boron (also known as p-B11 or p11 B), an abundant, environmentally sound fuel. Today the company is announcing, in collaboration with Japan’s National Institute for Fusion Science (NIFS), a noteworthy research advancement: the first-ever hydrogen-boron fusion experiments in a magnetically confined fusion plasma.

In a paper published by Nature Communications, scientists explain the outcome of the nuclear reaction of hydrogen-boron in an experiment in NIFS’ Large Helical Device (LHD). This paper describes the experimental work of producing the conditions necessary for hydrogen-boron fusion in the LHD plasma and TAE’s development of a detector to make measurements of the hydrogen-boron reaction products: helium nuclei, known as alpha particles.

The finding reflects years of collaborative international scientific fusion research, and represents a milestone in TAE’s mission to develop commercial fusion power with hydrogen-boron, the cleanest, most cost-competitive, and most sustainable cycle for fusion.